Details of the Drug
General Information of Drug (ID: DM7QPYK)
Drug Name |
SKF-106760
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
126053-71-2; F 106760; Skf 106760; F-106760; Ac-Cyclo-S,S-(cys-(N(alpha)-Me)arg-gly-asp-pen)-NH2; AC1Q5IR2; AC1L4UF1; [(4r,7s,13s,16r)-16-(acetylamino)-4-carbamoyl-13-{3-[(diaminomethylidene)amino]propyl}-3,3,14-trimethyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecan-7-yl]acetic acid; CTK4B4925; L-Valinamide,N-acetyl-L-cysteinyl-N2-methyl-L-arginylglycyl-L-a-aspartyl-3-mercapto-, cyclic (1& 5)-disulfide (9CI)
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 605.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -4.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 8 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 11 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Thrombosis | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | DB61-GB90 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||